The main clinical ingredient in Hydrate is Blis K12, manufactured by Stratum Nutrition in the USA.
"Bacteriocin-Like Inhibitory Substance" - BLIS
BLIS K12 produces two BLIS molecules with activity against bacteria and undesirable microorganisms.
MOST PATHOGENS ENTER THROUGH THE NOSE OR MOUTH
BLIS K12 populates the oral cavity particularly along the back of the tongue and ascends to the nasopharynx.
BLIS K12 reduced the incidence of Pharyngitis (sore throat) in children (3-13yrs) by 92%.
BLIS K12 reduced the incidence of Acute Otitis Media (ear infection) in children by 40% year over year.
BLIS K12 reduced the incidence of pharyngitis (sore throat) in adults by 84%.
Third study of BLIS K12 investigated both bacterial and viral causes of upper respiratory infections and the results were equally impressive.
CLINICAL TRIALS SUMMARY
- Dramatically reduces the incidence of select viral and bacterially induced ear infections and throat complaints.
- Reduces symptoms of secretory otitis media
- Helps reduce the use of antibiotics and antipyretics
- Helps decrease the likelihood of spreading a "bug" through social exposure.
- Helps reduce the cost and stress from days lost at work dues to seasonal upper respiratory infections.SUPPORT FOR HALITOSIS, DRY MOUTH AND MOUTH SORES
The main source of chronic bad breath, dry mouth and mouth sores is an imbalance of bacteria residing in the oral cavity.
Studies have found that sufferers have lower numbers of beneficial bacteria such as Streptococcus Salivarius. Therefore, we introduce this bacteria in BLIS K12 which addresses the root cause of "Bad Breath"
Hydrate vs. Antibacterial Mouthwash
- Kills all the good and bad
- Disturbs microbial balance
- Not Natural
- May increase blood pressure
- 24-Hour Protection
- Active colonization
- Selective inhibition of bad bacteria
- Restores microbial balance
- Cleanses the mouth
- Boosts Immune and Gut health
Clinical Study references
- Di Pierro F et al. (2012) Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med 5: 991-997.
- Di Pierro F et al. (2013) Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Salivarius pyogenes in adults. Exp Opin Biol Therapy 13(3): 339-343.
- Di Pierro F et al. (2014) Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf 6: 15-20.
- Di Pierro F et al. (2015) Oral use of Streptococcus salivarius K12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study. Int J Gen Med 8: 303-308.
- Gregori G et al. (2016) Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag 12: 87-92.
- Di Pierro F et al. (2016) Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci 20: 4601-4606.
- Di Pierro F et al. (2016) Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Drug Healthc Patient Saf 8: 77-81.
- Masdea L et al. (2012) Antimicrobial activity of Streptococcal salivarius K12 on bacteria involved in oral malodour. Arch Oral Biol 57(8): 1041-1047
- Burton J et al. (2006) A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol 100(4): 754-764.